Danielle Ternyila

Articles

Expert Highlights Encouraging PFS Data With Maintenance Ixazomib in Multiple Myeloma

February 21st 2019

Gareth Morgan, MD, discusses the TOURMALINE-MM3 findings in multiple myeloma and other clinical trials that are impacting the landscape for this patient population.

Ibrutinib/JCAR014 Combo Shows Potential in Relapsed/Refractory CLL

February 13th 2019

Jordan Gauthier, MD, MSc, discusses retrospective results of concurrent ibrutinib and JCAR014 and where chimeric antigen receptor T-cell research is headed for patients with chronic lymphocytic leukemia.

Following Progression on CAR T-Cell Therapy, B-Cell Lymphoma Treatment Options Needed

February 12th 2019

Victor A. Chow, MD, discusses the next steps in understanding how to treat patients with large B-cell lymphomas who progress after chimeric antigen receptor T-cell therapy.

Selinexor/Daratumumab Combo Shows Promise in Relapsed/Refractory Myeloma

January 22nd 2019

Cristina Gasparetto, MD, discusses the combination of daratumumab, selinexor, and dexamethasone in patients with multiple myeloma who have previously received ≥3 lines of therapy, which include an immunomodulatory agent and a proteasome inhibitor.

Luminary Awards in GI Cancers Honor Distinguished Leaders

November 30th 2018

Five leaders in the fight against gastrointestinal cancers from academia, the community, and clinic were honored at the 2018 Luminary Awards.

Gradishar Addresses 20 Years of Breast Cancer Advancements

October 14th 2018

William J. Gradishar, MD, discusses how far the breast cancer field has advanced over the last 20 years and the data he is anticipating to read out in the future.

Challenges Remain in Treating Patients With Phyllodes Breast Tumors

October 13th 2018

Andrea V. Barrio, MD, discusses the challenges with phyllodes tumors of the breast and how to manage this disease moving forward.

Expert Highlights Management of Locoregional Recurrence in Breast Cancer

October 13th 2018

Monica Morrow, MD, addresses how she treats patients with breast cancer who have locoregional recurrence and how therapeutic approaches have evolved over recent years.

Expert Shares Insights on CLL Treatment Paradigm

July 20th 2018

Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.

Expert Discusses the Discontinuation of TKIs in Treatment Landscape of CML

July 14th 2018

Gabriela S. Hobbs, MD, discusses how discontinuing tyrosine kinase inhibitors will change the treatment landscape and other strategies for treating patients with chronic myeloid leukemia.

O'Reilly Discusses Status of Immunotherapy Research in Pancreas Cancer

June 22nd 2018

Eileen M. O’Reilly, MD, speaks to the progress being made with immune therapies in pancreatic cancer.

Conroy Highlights Practice-Changing Findings With Chemo Combo in Pancreatic Cancer

June 21st 2018

Thierry Conroy, MD, discusses the PRODIGE 24/CCTG PA.6 trial and shares his insight on future research with this treatment regimen.